Moleculin Biotech, Inc.
MBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | 0.04 | -0.00 | 0.24 |
| FCF Yield | -1.46% | -4.76% | -200.68% | -3.54% |
| EV / EBITDA | -19.23 | -14.46 | 0.84 | -75.53 |
| Quality | ||||
| ROIC | -39.90% | -41.43% | -41.73% | -56.85% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.28 | 0.73 | 0.71 | 2.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -29.40% | -22.30% | 10.21% | 16.85% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.94 | 1.23 | 2.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,068.57 | -11,547.93 | 0.00 | -5,893.55 |